GlassScriptPhysician profile
Charles M Jackson
NPI 1255659082
$8,734.03
in general payments reported to CMS, 2019-2025
30 companies · $1,595 in 2025
The $1,595 reported for 2025 was more than what 75% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $103 · 2021: $1,703 · 2022: $810 · 2023: $2,517 · 2024: $1,587 · 2025: $1,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,353 · Travel and Lodging: $1,077 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,352.93 |
| Travel and Lodging | $1,076.82 |
| Education | $270.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $1,982.94 | 2021-2025 | Aquabeam System, Aquabeam Robotic System |
| Axonics, INC. | $1,754.02 | 2023-2024 | Axonics, Bulkamid |
| Teleflex LLC | $769.87 | 2024-2025 | Barrigel, Urolift |
| Coloplast Corp | $669.93 | 2019-2025 | Titan |
| Boston Scientific Corporation | $599.58 | 2019-2025 | Spaceoar Vue System - 10ml, Spaceoar System, Axonics |
| Medtronic, INC. | $575.77 | 2021-2025 | Interstim, Altaviva |
| Astellas Pharma US INC | $488.29 | 2019-2024 | Xtandi |
| Sumitomo Pharma America, INC. | $279.76 | 2023-2025 | Orgovyx |
| Endo Pharmaceuticals INC. | $217.25 | 2019-2024 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $198.02 | 2022-2025 | Jelmyto |
| Abbvie INC. | $145.50 | 2023-2025 | |
| Cook Medical LLC | $142.81 | 2019-2025 | |
| Janssen Biotech, INC. | $130.86 | 2019-2025 | Erleada, Akeega |
| Pfizer INC. | $93.22 | 2019-2025 | |
| Photocure INC | $72.97 | 2023-2025 | Cysview |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $72.31 | 2020-2021 | |
| Endo USA, INC. | $53.40 | 2024-2025 | Xiaflex |
| Myovant Sciences INC. | $50.88 | 2022 | |
| Myriad Genetic Laboratories, INC. | $49.84 | 2023-2025 | Prolaris |
| Neotract INC. | $48.77 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $48.30 | 2023-2024 | Exparel |
| Dendreon Pharmaceuticals LLC | $42.06 | 2019 | |
| Blue Earth Diagnostics | $40.22 | 2021-2022 | |
| Ethicon US, LLC | $39.56 | 2024 | Harmonic |
| Merck Sharp & Dohme LLC | $37.94 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $34.95 | 2019-2022 | |
| Medtronic USA, INC. | $32.20 | 2019-2020 | |
| Tolmar, INC. | $25.98 | 2023 | |
| Innovation Technologies INC | $24.80 | 2024 | Irrisept |
| Genentech USA, INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.